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INTRODUCTION 
Hepatitis C virus (HCV) is an RNA virus that is unable to inte-
grate into the host genome. However, its proteins interact with 
various host proteins and induce host responses that potentially 
contribute to the malignant transformation of cells. Hepatocellular 
carcinoma (HCC) development is usually a final consequence of 
sequential progression of chronic fibrosing liver diseases, and HCC 
usually occurs only after establishment of liver cirrhosis in HCV-
infected individuals.
1 In cirrhotic patients with HCV infection, the 
annual HCC development rates range between 1-7%.
2
The incidence of HCV-related HCC continues to rise and is esti-
mated to remain high in the next two decades.
3 Although epide-
miological evidence has suggested a clear, close relationship be-
tween HCV infection and HCC,
4,5 the prevalence of HCV infection 
in HCC patients differs noticeably between geographical regions. 
HCV infection is found in 70-80% of HCC patients in Japan, 70% 
in Egypt, 40-50% in Italy and Spain, about 20% in the United 
States and Korea, and less than 10% in China.
6-8 HCV increases 
the risk of HCC by promoting inflammation and fibrosis of the 
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infected liver that eventually results in liver cirrhosis. Other factors 
including alcohol intake, diabetes, and obesity have also been 
reported to increase the risk of HCC development by about two- 
to fourfold, indicating a strong life-style effect on the process of 
hepatocarcinogenesis.
9,10
Recent genome-wide association studies (GWAS) have suggest-
ed that the natural course of HCV infection might be modified by 
the genetic background of the host.
11,12 Thus, both host and virus 
factors are considered to affect the process of hepatocarcinogen-
esis in a complex manner.
In this review, we summarize the current knowledge of the 
mechanisms of hepatocarcinogenesis induced by HCV infection.
Molecular pathways in hepatocarcinogenesis
HCC is a highly heterogeneous tumor. Hepatocarcinogenesis is 
a complex multistep process involving a number of genetic and 
epigenetic alterations, the activation of cellular oncogenes and/
or the inactivation of tumor suppressor genes, and dysregulation 
of multiple signal transduction pathways. These pathways include 
Wnt/β-catenin, p53, pRb, Ras, mitogen-activated protein kinase 
(MAPK), Janus kinase (JAK)/signal transducer and activator of 
transcription (STAT), phosphatidylinositol 3-kinase (PI3K)/Akt, 
Hedgehog and growth factors such as epidermal growth factor, 
and transforming growth factor-β (TGF-β) pathways.
13-15
Fibrosis and hepatocarcinogenesis
The vast majority (80-90%) of HCCs develop in a cirrhotic liver.
16 
During the progression of liver injury, hepatic stellate cells (HSCs) 
become activated, losing retinoid-containing lipid droplets and 
transforming into myofibroblast-like cells, which produce extracel-
lular matrix, the first step in hepatic fibrosis.
17 Unchecked progres-
sion of fibrosis ultimately eventuates in irreversible cirrhosis. The 
activated HSCs become responsive to both proliferative platelet-
derived growth factor (PDGF)
18 and fibrogenic (TGF-β) cytokines,
19 
which are upregulated in fibrogenesis and modulate inflammatory 
signaling from infiltrating immune cells.
20 PDGF can activate both 
MAPK and PI3K/Akt signaling cascades.
20 In PDGF-C transgenic 
mice, activation and proliferation of HSCs precedes development 
of fibrosis, which in turn is followed by the occurrence of HCC. 
This progression is analogous to that seen in human HCC.
21 The 
cirrhotic liver is also associated with telomere shortening, which 
may in turn lead to chromosomal instability and deletion of check 
points.
22 Increased survival factors that prevented apoptosis of 
DNA-damaged hepatocytes and activated stellate cells (for ex-
ample, Gas6
215) and reduced tumor surveillance function due to 
decreased natural killer cell function are all possible factors related 
to HCC development in cirrhosis.
23 Recent studies have found that 
stellate cells express stem cell markers such as CD133, nestin, 
c-kit and p75 neurotrophin receptor,
24-27 and activated stellate 
cells appear to contribute to the stem cell niche.
28 Hedgehog and 
Wnt signaling pathways involved in stem cell differentiation and 
cancer formation are also found in stellate cells.
29,30 These lines of 
evidences suggest that stellate cells may harbor the potential to 
transdifferentiate into progenitor cells and possibly be linked to 
the development of HCC.
23
Virus proteins and host responses
HCV belongs to the Flaviviridae family. It has a 9.6-kb positive-
stranded linear RNA genome containing 5’ and 3’ untranslated 
regions including control elements required for translation and 
replication. The untranslated regions flank an uninterrupted open-
reading frame encoding a single polyprotein of 3010 or 3011 
amino acids, which is processed into three structural (core, E1, and 
E2) and seven non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A, 
and NS5B) proteins by host and viral proteases.
31 HCV is an RNA 
virus unable to reverse transcribe its genome and thus to integrate 
it into the host genome. Instead, viral proteins and their evoked 
host responses contribute mostly to the viral oncogenic processes.
Core protein
HCV core protein has been proposed to be involved in apopto-
sis, signal transduction, reactive oxygen species (ROS) formation, 
lipid metabolism, transcriptional activation, transformation and 
immune modulation (Fig. 1).
15,32
Several recent studies have indicated the statistically significant 
high frequency of mutations in the core gene in HCV-infected pa-
tients who developed HCC.
33,34 
HCV core protein binds to several tumor suppressor proteins, 
including p53, p73 and pRb.
35,36 HCV core interacts with p73, 
causes nuclear translocation of core protein and prevents p73 
α-dependent cell growth arrest in a p53-dependent manner.
37 
HCV core can also modulate the expression of the cyclin depen-
dent inhibitor p21
WAF1, which is a major target of p53 and regu-
lates the activities of cyclin/cyclin-dependent kinase complexes 
involved in cell-cycle control and tumor formation.
38,39 Core pro-
tein may also influence the growth and proliferation of host cells 
through activation of signaling pathways such as Raf/MAPK,
40 349
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Wnt/β-catenin,
41 and TGF-β.
15,42 These pathways are known to be 
activated in HCC.
43 However, the functional relevance of mutant 
core proteins on the malignant transformation of hepatocytes or 
the HCV life cycle has yet to be clarified. 
NS3 protein
HCV NS3 protein may exert its hepatocarcinogenic effect on 
host cells in early stages.
44,45 
NS3 inhibits the activity of the p21
WAF1 promoter in a dose-
dependent manner and is synergistic with core in this regard.
46 
NS3 inhibits the function of p53 in an NS3 sequence in an NS3 
sequence-dependent manner.
47 The expression of NS3 enhances 
cell growth, JNK activation and DNA-binding activities of the 
transcription factors AP-1 and ATF-2.
48 NS3 also induces TNF-a 
production by activation of AP-1 and NF-kB.
49
NS5A protein
NS5A is essential for the replication of the HCV genome and is 
localized mainly in the cytoplasm of infected cells in association 
with the endoplasmic reticulum (ER). NS5A is involved in a large 
number of cellular functions, including apoptosis, signal transduc-
tion, transcription, transformation and ROS production. High fre-
quencies of wild-type NS5A genes were reported to be dominant 
in liver cirrhosis patients who finally developed HCC compared 
with those who did not,
50 but the mechanistic significance of the 
NS5A wild/mutant genotypes in the process of HCV-related hepa-
tocarcinogenesis remains uncertain. NS5A protein has been sug-
gested to interact with various signaling pathways including cell 
cycle/apoptosis
51 and lipid metabolism
52-54 in host cells and shares 
some signaling targets with core protein. NS5A is recognized as 
a transcriptional activator for many target genes
55 including p53 
and its binding protein, TATA binding protein (TBP). Transcrip-
tion factor IID activities were reported to be modified by NS5A in 
the suppression of p53-dependent transcriptional transactivation 
and apoptosis.
56,57 NS5A may also interact with pathways such as 
Bcl2,
58 PI3-K,
59 Wnt/β-catenin signaling,
60 and mTOR
61 to activate 
cell proliferation signaling and inhibit apoptosis. Taken together, 
intriguing data concerning the function of core and NS5A proteins 
on host cell signaling pathways, transcriptional activation, apop-
tosis, oxidative stress, and lipid metabolism suggest a diverse role 
for HCV proteins in the pathophysiology of chronic HCV infection 
that leads to malignant transformation in infected hepatocytes. 
Genomic characteristics of HCV related HCC
It is now widely believed that tumors originate from normal cells 
as a result of accumulated genetic/epigenetic changes. These al-
terations affect the signaling pathways at transcriptional and post-
transcriptional level that drive cells into uncontrolled cell division, 
growth, and migration. HCV proteins in infected cells can cause 
various host responses at transcriptional/translational/posttrans-
latonal levels, so genetic/genomic alterations and transcriptional/
translational modifications can ultimately affect the cellular signal-
ing pathway at the transcriptional level.
Figure 1. Cellular signaling pathways implicated in hepatitis C virus (HCV) core protein-related hepatocarcinogenesis. 
Blue boxes indicate key driving forces for carciniogenesis.350
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Recent advancement of molecular technologies have yielded 
comprehensive gene expression profiling techniques that have 
successfully provided candidate diagnostic and prognostic markers 
in human cancers.
Over the past decade, several methods (including differential 
display, serial analysis of gene expression [SAGE], and microarray) 
have been developed to allow comparative studies of gene expres-
sion between normal and cancer cells on a genome-wide scale,
62 
and the analysis of a set of all RNA molecules (mainly indicating 
messenger RNAs [mRNAs]) is termed as whole transcriptome 
analysis.
Early microarray and SAGE studies investigating the gene ex-
pression patterns of chronic hepatitis B (CHB) and CHC indicated 
that many genes were differentially regulated between hepatitis B 
and C. In CHB, genes for induction of apoptosis, cell cycle arrest, 
and extracellular matrix degrading were up-regulated, whereas in 
hepatitis C, genes with antiapoptotic effects, cell cycle accelera-
tion, and extracellular matrix storage were up-regulated.
63,64
An early study comparing genes activated in HCV-related and 
HBV-related HCCs showed that expression of genes encoding 
CYP2E, AKR1C4, EPHX1, and FMO3 enzymes that convert several 
pro-carcinogens to activated metabolites increased exclusively 
in HCV-positive HCCs, which may suggest that their enhanced 
expression leads to a greater contribution of carcinogenic metabo-
lites to the mechanisms of HCV-specific hepatocarcinogenesis. On 
the other hand, decreased expression of detoxification enzymes 
including UGT1A1, UGT2B10, and GPX2 was noted in HBV-
positive HCCs. These results suggest that decreased expression of 
detoxification enzymes may be involved especially in the mecha-
nisms of HBV-specific hepatocarcinogenesis.
The genes associated with xenobiotic metabolism were more 
abundantly expressed in HCV-related HCC, suggesting a detoxifi-
cation role, which is potentially induced by chronic inflammation 
and generation of ROS resulting from HCV infection.
65 In contrast, 
HBV-related HCC might closely correlate with the activation of 
imprint genes, including insulin-like growth factor-II (IGF-II), sug-
gesting a role of de-differentiation or epigenetic alteration of the 
host genome in HBV-related HCC. The expression levels of many 
detoxification-related genes were increased in HCV-related HCC 
in comparison to HBV-related HCC. Markedly reduced levels of 
detoxification-related genes in HBV-related HCC suggests that 
HBV-infected liver could be more susceptible than HCV-infected 
liver to various xenobiotics or carcinogens.
66 Activation of genes 
associated with interferon, oxidative stress, apoptosis, and lipid 
metabolism signaling was detected in HCV-related HCC and CHC 
specimens,
64,67,68 consistent with numerous functional studies that 
have investigated the host response evoked by HCV structural and 
non-structural proteins.
51
HCC risk predictors that identify the subset of cirrhotic patients 
with the highest risk of HCC are sorely needed. In addition, iden-
tification of molecular biomarkers may open new prospect toward 
the discovery of therapeutic targets.
Transcriptome analysis has also recently gave new understand-
ing on the transcriptional alteration events occurring in early stag-
es of HCV-related hepatocarcinogenesis. GPC3 (encoding Glypican 
3) was suggested as one of the most activated transcripts in the 
early stage of hepatocarcinogenesis,
64,69 also several recent stud-
ies have reported that gene signatures including GPC3 can suc-
cessfully discriminate HCCs from pre-malignant dysplastic nodules 
and cirrhosis nodules.
70,71
The genetic approach between each of the stages from normal, 
cirrhotic, and dysplastic to early and advanced HCV-related HCC 
identified gene signatures that accurately reflect the pathological 
progression of disease at each stage. In addition, pathway analy-
sis revealed dysregulation of the Notch and Toll-like receptor path-
ways in cirrhosis, followed by deregulation of several components 
of the JAK/STAT pathway in early carcinogenesis, then upregula-
tion of genes involved in DNA replication and repair and cell cycle 
in late cancerous stages.
50,72 These findings provide a comprehen-
sive molecular portrait of genomic changes in progressive HCV-
related HCC. Aimed at identifying etiology-specific or independent 
genetic variants predictive of HCC risk, efforts have focused on 
the search for single nucleotide polymorphisms (SNPs) associated 
with the presence of HCC in candidate genes such as epidermal 
growth factor (EGF) based on certain biological hypothesis.
73 
Recent development of high-throughput genomics technology 
has enabled genome-wide scans of such loci in the setting of a 
GWAS. In HCC, the first GWAS was conducted on hepatitis B-
related HCC patients and identified a SNP possibly associated with 
altered expression and function of several potential tumor sup-
pressor genes in 1p36.22 namely KIF1B, UBE4B, and PGD.
74 
The first GWAS on HCV-related HCC has recently been reported 
by Kumar and colleagues.
75 By analyzing 721 patients with HCV-
related HCC and 2890 HCV-negative controls of Japanese origin 
for 432,703 autosomal SNPs, they identified eight possible HCC 
susceptibility loci with modest statistical significance. The follow-
ing replication stage, involving 673 independent cases and 2596 
HCV-negative controls, confirmed a novel SNP rs2596542 located 
in the 50 flanking region of MICA, the MHC class I polypeptide-
related sequence A gene, on chromosome 6p21.33.351
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The authors further genotyped the locus in additional 1730 
individuals with CHC who had not developed liver cirrhosis, and 
found that the association of the risk allele was observed in the 
comparison between CHC and HCC patients, but not in the com-
parison between CHC patients and HCV-negative controls, sug-
gesting that the SNP is associated with progression from CHC to 
HCC rather than susceptibility to HCV infection. 
However, the study by Kumar et al
75 did not use HCV-related 
cirrhosis without HCC as the controls, it is possible that the risk 
allele in the MICA gene is actually responsible for increased pro-
gression of liver cirrhosis, which eventually contributes to develop-
ment of HCC. That is, information from this allele may not be use-
ful in distinguishing HCC high risk population among HCV related 
cirrhotic patients. In fact, the soluble MICA protein level was not 
different between CHC, cirrhosis, and HCC patients. This needs to 
be clarified in future studies for example by genotyping patients 
with HCV-related cirrhosis and following for HCC development to 
evaluate the risk allele’s association with hazard of HCC occur-
rence within cirrhotic patients.
76
The study by Miki et al
77 is the last of a recent series of GWAS 
focused on HCC (Table 1).
78
Authors analyzed a large set of HCV Japanese carriers (n=3,312) 
using a case-control design, and they interrogated 467,538 germ-
line SNPs and identified one, rs1012068, significantly associated 
with the risk of developing HCC. The SNP is located in chromo-
some 22, and by using fine mapping studies the authors identified 
DEPDC5 as the target gene harboring the different genotypes. De-
spite the function of this gene is unknown, there is some evidence 
of aberrations affecting its locus in human cancer (e.g., glioblas-
toma). 
Recent advances in transcriptome analysis have also provided 
detailed information on the status of small noncoding RNAs, 
microRNAs (miRNAs) that regulate gene expression by target-
ing mRNAs through translational repression or RNA degrada-
tion. Many fundamental biological processes are modulated by 
miRNAs, and an important role for miRNAs in carcinogenesis is 
emerging.
Although the mechanisms of altered miRNA levels in human 
cancer are quite varied, including deletions, amplification or mu-
tations involving miRNA genes, it is clear that miRNA-regulated 
expression of oncogenes and tumor suppressor genes contribute 
to most – if not all – human cancers.
1 Earlier studies noted specific 
changes in miRNA expression patterns in HCC as compared with 
adjacent normal liver tumor tissues, or liver cirrhosis that corre-
lated with the disease outcome (Table 2).
3,81-84
Since there is no HCV encoded oncoprotein, the question arises 
whether the deregulated miRNAs in HCC serve as “oncomiRs,” 
that could function as an oncogene or a tumor suppressor, to reg-
ulate cell proliferation by targeting cell cycle check points and/or 
growth factors. Such oncomiRs in liver cancer would be expected 
to be involved through each step from normal liver to cirrhosis to 
HCC. The extant literature strongly supports the role of specific 
oncoMirs in the development and maintenance of HCC. 
More recently, the investigators focused on miR-26a whose ex-
pression is most significantly perturbed in MYC-induced liver can-
cer model.
87 MiR-26a targets expression of cyclins D2 and E2; and 
ectopic expression of miR-26a induced G1 arrest in HepG2 HCC 
cell line. Examination of paired biopsies from normal human liver 
tissues as compared with liver cancer showed consistent reduction 
of miR-26a in liver cancer, while miR-26a is expressed at high lev-
els in normal liver as well as other tissues. Since miR-26a induces 
G1 arrest by targeting cyclins D2 and E2, the authors reasoned 
that forced expression of miR-26a in liver cancer cells might arrest 
tumor growth.
Indeed, the systemic administration of miR-26a in a mouse 
model of HCC using adeno-associated virus vector system, result-
ed in the inhibition of cancer cell proliferation by inducing tumor-
specific apoptosis, with dramatic protection from disease progres-
Table 1. Published GWAS in hepatocellular carcinoma (Adapted from Villanueva A, et al. J Hepatol 2012;57:213-214)
78
Article
Sample analyzed Etiology of 
liver disease
DNA regions 
identified
Candidate 
genes
Effect size/Odds ratio 
(95% CI) HCC (validation) Controls (validation) Total
Miki D
70 212 (710)   765 (1625) 3312 HCV Chr 22q12.2 DEPDC5 1.75 (1.51-2.03)
Kumar V
71 721 (673) 2890 (2596) 6880 HCV Chr 6p21.33 MICA 1.39 (1.27-1.63)
Zhang H
77  348 (1962)   359 (1430) 4099 HBV Chr 1p36.22 UBE4B-
KIF1B-PDG
 0.61 (0.55-0.67)
Clifford RJ
78 180 (337) 206 (336) 1059 HBV, HCV Chr 13q12.11 TPTE2 0.27 (0.19-0.39)
Chr 2q14.1 Non-coding 3.38 (2.07-5.52)
HCC, hepatocellular carcinoma;  HCV, hepatitis C virus;  HBV, hepatitis B virus;  Chr, chromosome; MICA, MHC class I polypeptide-related sequence A gene.352
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sion without toxicity.
87
Thus, the delivery of miR-26a, which is highly expressed and 
therefore tolerated in normal, but not in liver cancer cells, may be 
a useful strategy for miRNA-replacement therapy for HCC.
89
Expression of miRNAs including miR-122 and -199a has been 
reported to modulate HCV replication,
3,85,90 and miR-122 expres-
sion can be regulated by host interferon signaling and responses.
52 
HCV induced miR-155 expression promotes hepatocyte prolifera-
tion and tumorigenesis by activating Wnt signaling. The overex-
pression of miR-155 significantly inhibited hepatocyte apoptosis 
and promoted cell proliferation.
91
HCV protein expression in turn could induce miRNAs and might 
affect the tumor suppressor DLC1 and the chemosensitivity of 
malignantly transformed cells.
53,88 Several miRNAs were also dif-
ferentially expressed between HCV-related and HBV-related HCCs 
as well as their corresponding non-cancerous liver tissues. The 
candidate signaling pathways potentially altered by miRNAs in 
HCV-related tissues were those associated with antigen presenta-
tion, cell cycle, and lipid metabolism,
92 consistent with the mRNA 
microarray data described above. MiRNAs have also recently 
been reported to successfully discriminate between HCC and cir-
rhotic liver tissues,
55 implicating their role in the early stages of 
Table 2. Selected examples of reported alterations in miRNA expression in HCV infection and their proposed role in Hepatocellular carcinoma 
(Adapted from Kumar A, et al. Biochimica et biophysica acta 2011;1809:694-699).
84
Selected examples of microRNAs in HCV infection and Hepatocellular carcinoma
MicroRNA Target Phenotype References
MiR-122 HCV 5’-UTR Viral RNA amplification 85,86
MicroRNA alterations Not validated HCC/normal tissue HCV Inf.HCC 81
Mir-199a HCV 5’-UTR Suppression of HCV replication 3
MiR-181 Transcription regulation Up regulated in HCC 73
Mir-221 CDK inhibitor Up regulated in HCC 74
Mir-199a Predicted cell Increased expression in HCC 83
Mir-21, Mir-301 Cycle genes
Mir-26a Cyclin D2/E2 Reduced expression in HCC 87
Mir-141 DLC-1 Up regulated HCV infection 88
HCV, hepatitis C virus;  UTR, untranslated region;  HCC, hepatocellular carcinoma; Inf., infected; CDK, cyclin-dependent kinase; DLC-1, a Rho GTPase-
activating protein.
Figure 2. Hepatitis C virus and hepatocarcinogenesis.353
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malignant transformation. These data suggest that miRNAs may 
be good targets for the eradication of HCC as well as hepatocytes 
infected with HCV.
CONCLUSION
Hepatocarcinogenesis is a multistep process and involves 
multiple cellular signaling pathways. Although HCV is the ma-
jor risk factors leading to the development of HCC, the precise 
pathogenetic mechanisms linking viral infection and HCC remain 
uncertain. Viral proteins also have been implicated in disrupting 
several cellular signal transduction pathways that affect cell sur-
vival, proliferation, migration and transformation (Fig. 2).
15 Current 
advances in gene expression profile and selective mRNA analysis 
have improved approach to the pathogenesis of HCC. The het-
erogeneity of genetic events observed in HCV-related HCCs has 
suggested that complex mechanisms underlie malignant transfor-
mation induced by HCV infection. Considering the complexity and 
heterogeneity of HCCs of both etiological and genetic aspects, 
further molecular classification is required and an understanding 
of these molecular complexities may provide the opportunity for 
effective chemoprevention and personalized therapy for HCV-
related HCC patients in the future.
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